{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:50:30Z","timestamp":1769608230436,"version":"3.49.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1713","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved an epinephrine nasal spray (neffy \u2013 ARS Pharma) for emergency treatment of type 1 hypersensitivity reactions including anaphylaxis in patients who weigh \u226530 kg. It is the first noninjectable epinephrine product to be approved for this indication.<\/jats:p>","DOI":"10.58347\/tml.2024.1713b","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T18:57:31Z","timestamp":1727809051000},"page":"163-164","source":"Crossref","is-referenced-by-count":2,"title":["An Epinephrine Nasal Spray (neffy) for Anaphylaxis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,10,14]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T18:57:32Z","timestamp":1727809052000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1713b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":0,"journal-issue":{"issue":"1713","published-online":{"date-parts":[[2024,10,14]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1713b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}